Search

Your search keyword '"Pierga, Jean-Yves"' showing total 998 results
Start Over Author "Pierga, Jean-Yves"
998 results on '"Pierga, Jean-Yves"'

4. Concomitant medication, comorbidity and survival in patients with breast cancer

Author

Dumas, Elise, Grandal Rejo, Beatriz, Gougis, Paul, Houzard, Sophie, Abécassis, Judith, Jochum, Floriane, Marande, Benjamin, Ballesta, Annabelle, Del Nery, Elaine, Dubois, Thierry, Alsafadi, Samar, Asselain, Bernard, Latouche, Aurélien, Espie, Marc, Laas, Enora, Coussy, Florence, Bouchez, Clémentine, Pierga, Jean-Yves, Le Bihan-Benjamin, Christine, Bousquet, Philippe-Jean, Hotton, Judicaël, Azencott, Chloé-Agathe, Reyal, Fabien, and Hamy, Anne-Sophie

Published
2024
Full Text
View/download PDF

5. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy

Author

Malhaire, Caroline, Selhane, Fatine, Saint-Martin, Marie-Judith, Cockenpot, Vincent, Akl, Pia, Laas, Enora, Bellesoeur, Audrey, Ala Eddine, Catherine, Bereby-Kahane, Melodie, Manceau, Julie, Sebbag-Sfez, Delphine, Pierga, Jean-Yves, Reyal, Fabien, Vincent-Salomon, Anne, Brisse, Herve, and Frouin, Frederique

Published
2023
Full Text
View/download PDF

7. Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program

Author

de Moura, Alexandre, Vuagnat, Perrine, Renouf, Benjamin, Pierga, Jean-Yves, Loirat, Delphine, Vaflard, Pauline, Lafayolle de la Bruyère, Charline, Chaumard-Billotey, Natacha, Hajjaji, Nawale, Ladoire, Sylvain, Dabakuyo, Sandrine, Patsouris, Anne, Frenel, Jean Sébastien, Nicolai, Vincent, Alexandre, Marie, Dohollou, Nadine, Grenier, Julien, Bourien, Heloïse, and Bidard, François-Clément

Published
2023
Full Text
View/download PDF

9. Evolution of synchronous female bilateral breast cancers and response to treatment

Author

Hamy, Anne-Sophie, Abécassis, Judith, Driouch, Keltouma, Darrigues, Lauren, Vandenbogaert, Mathias, Laurent, Cecile, Zaccarini, Francois, Sadacca, Benjamin, Delomenie, Myriam, Laas, Enora, Mariani, Odette, Lam, Thanh, Grandal, Beatriz, Laé, Marick, Bieche, Ivan, Vacher, Sophie, Pierga, Jean-Yves, Brain, Etienne, Vallot, Celine, Hotton, Judicael, Richer, Wilfrid, Rocha, Dario, Tariq, Zakia, Becette, Veronique, Meseure, Didier, Lesage, Laetitia, Vincent-Salomon, Anne, Filmann, Natalie, Furlanetto, Jenny, Loibl, Sibylle, Dumas, Elise, Waterfall, Joshua J., and Reyal, Fabien

Published
2023
Full Text
View/download PDF

11. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Author

Magbanua, Mark Jesus M, Hendrix, Laura H, Hyslop, Terry, Barry, William T, Winer, Eric P, Hudis, Clifford, Toppmeyer, Deborah, Carey, Lisa Anne, Partridge, Ann H, Pierga, Jean-Yves, Fehm, Tanja, Vidal-Martínez, José, Mavroudis, Dimitrios, Garcia-Saenz, Jose A, Stebbing, Justin, Gazzaniga, Paola, Manso, Luis, Zamarchi, Rita, Antelo, María Luisa, De Mattos-Arruda, Leticia, Generali, Daniele, Caldas, Carlos, Munzone, Elisabetta, Dirix, Luc, Delson, Amy L, Burstein, Harold J, Qadir, Misbah, Ma, Cynthia, Scott, Janet H, Bidard, François-Clément, Park, John W, and Rugo, Hope S

Subjects
Cancer, Prevention, Breast Cancer, Clinical Research, Breast Neoplasms, Female, Humans, Neoplastic Cells, Circulating, Prognosis, Progression-Free Survival, Proportional Hazards Models, Reproducibility of Results, Retrospective Studies, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundWe examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.MethodsSerial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.ResultsLatent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.ConclusionsWe identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.

Published
2021

13. Microsatellite instability detection in breast cancer using drop-off droplet digital PCR

Author

Klouch, Khadidja Zeyneb, Stern, Marc-Henri, Trabelsi-Grati, Olfa, Kiavue, Nicolas, Cabel, Luc, Silveira, Amanda Bortolini, Hego, Caroline, Rampanou, Aurore, Popova, Tatiana, Bataillon, Guillaume, Nasr, Sarah, Proudhon, Charlotte, Michel, Marc, Renault, Victor, Masliah Planchon, Julien, Vincent-Salomon, Anne, Pierga, Jean-Yves, Bieche, Ivan, Renault, Shufang, and Bidard, François-Clément

Published
2022
Full Text
View/download PDF

14. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

Author

Delaloge, Suzette, Piccart, Martine, Rutgers, Emiel, Litière, Saskia, van 't Veer, Laura J, van den Berkmortel, Franchette, Brain, Etienne, Dudek-Peric, Aleksandra, Gil-Gil, Miguel, Gomez, Patricia, Hilbers, Florentine S, Khalil, Zaman, Knox, Susan, Kuemmel, Sherko, Kunz, Georg, Lesur, Anne, Pierga, Jean-Yves, Ravdin, Peter, Rubio, Isabel T, Saghatchian, Mahasti, Smilde, Tineke J, Thompson, Alastair M, Viale, Giuseppe, Zoppoli, Gabriele, Vuylsteke, Peter, Tryfonidis, Konstantinos, Poncet, Coralie, Bogaerts, Jan, and Cardoso, Fatima

Subjects
Genetics, Rare Diseases, Breast Cancer, Clinical Trials and Supportive Activities, Human Genome, Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Capecitabine, Docetaxel, Female, Humans, Middle Aged, Prospective Studies, MINDACT investigators and the TRANSBIG Consortium, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. A second random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regimen.Patients and methodsR-C randomly assigned patients 1:1 between standard anthracycline-based regimens, with or without taxanes (control) and experimental docetaxel 75 mg/m2 intravenously plus oral capecitabine 825 mg/m2 two times per day for 14 days (DC) every 3 weeks for 6 cycles. The primary end point was disease-free survival (DFS). Secondary end points included overall survival and safety.ResultsOf 2,832 patients, 1,301 (45%) were randomly assigned, and 97% complied with R-C assignment. In the control arm, 29.6% only received taxanes (0.5% of N0 patients). DFS events (n = 148) were much less than required (n = 422) as a result of a lower-than-expected accrual and event rate. At 5 years of median follow-up, DFS was not different between DC (n = 652) and control (n = 649; 90.7% [95% CI, 88% to 92.8%] v 88.8% [95% CI, 85.9% to 91.1%]; hazard ratio [HR], 0.83 [95% CI, 0.60 to 1.15]; P = .26). Overall survival (HR, 0.91 [95% CI, 0.54 to 1.53]) and DFS in the clinical high and genomic high-risk subgroup (86.1% v 88.1%; HR, 0.83 [95% CI, 0.58 to 1.21]) were similar in both arms. DC led to more grade 1 neuropathy (27.1% v 11.2%) and more grade 2 hand/foot syndrome (28.5% v 3.3%) and diarrhea (13.7% v 5.8%). Serious cardiac events occurred in 9 patients (control, n = 4; DC, n = 5). Fifty-three patients developed second cancers (control, n = 32; DC, n = 21; leukemia: 2 v 1). Five treatment-related deaths occurred (control, 2 [0.3%]; DC, 3 [0.5%]).ConclusionAlthough underpowered, this second randomization in MINDACT did not show any improvement in outcome or safety with the use of DC compared with anthracycline-based chemotherapy.

Published
2020

15. Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS

Author

Chvetzoff, Gisèle, Bouleuc, Carole, Lardy-Cléaud, Audrey, Saltel, Pierre, Dieras, Véronique, Morelle, Magali, Guastalla, Jean-Paul, Tredan, Olivier, Rebattu, Paul, Pop, Simona, Ray-Coquard, Isabelle, Pierga, Jean-Yves, Mignot, Laurent, Laurence, Valérie, Bourne-Branchu, Valérie, Pérol, David, and Bachelot, Thomas

Published
2023
Full Text
View/download PDF

17. Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France

Author

Petit, Thierry, primary, Hajjaji, Nawale, additional, Antoine, Eric‐Charles, additional, Benderra, Marc‐Antoine, additional, Gozy, Michel, additional, Foa, Cyril, additional, Mouysset, Jean‐Loup, additional, Grenier, Julien, additional, Mousseau, Mireille, additional, Mailliez, Audrey, additional, Saghatchian, Mahasti, additional, Lachaier, Emma, additional, Desmoulins, Isabelle, additional, Hennequin, Audrey, additional, Maes, Patricia, additional, Loirat, Delphine, additional, Ricci, Francesco, additional, Diéras, Véronique, additional, Berton, Dominique, additional, Tiong, Florence Lai, additional, Teixeira, Luis, additional, Dohollou, Nadine, additional, Lévy, Christelle, additional, Bachelot, Thomas, additional, and Pierga, Jean‐Yves, additional

Published
2024
Full Text
View/download PDF

18. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer

Author

Guarneri, Valentina, primary, Passos Coelho, José Luís, additional, Duhoux, Francois P, additional, Egle, Daniel, additional, García-Sáenz, José Ángel, additional, Penault-Llorca, Frédérique, additional, Selander, Katri, additional, Wildiers, Hans, additional, Zaman, Khalil, additional, Laeis, Petra, additional, Lucerna, Markus, additional, and Pierga, Jean-Yves, additional

Published
2024
Full Text
View/download PDF

19. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer

Author

Frenel, Jean-Sebastien, primary, Zeghondy, Jean, additional, Guérin-Charbonnel, Catherine, additional, Mailliez, Audrey, additional, Volant, Elsa, additional, Poumeaud, François, additional, Patsouris, Anne, additional, Arnedos, Monica, additional, Bailleux, Caroline, additional, Cabal, Julie, additional, Galland, Loick, additional, de Nonneville, Alexandre, additional, Guiu, Séverine, additional, Dalenc, Florence, additional, Pistilli, Barbara, additional, Bachelot, Thomas, additional, Pierga, Jean-Yves, additional, Le Du, Fanny, additional, Bocquet, François, additional, Larrouquere, Louis, additional, and Loirat, Delphine, additional

Published
2024
Full Text
View/download PDF

20. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Author

BIDARD, Francois-Clement, PISTILLI, Barbara, DALENC, Florence, BACHELOT, Thomas, DE LA MOTTE ROUGE, Thibault, SABATIER, Renaud, DUBOT, Coraline, FRENEL, Jean-Sébastien, FERRERO, Jean-Marc, LADOIRE, Sylvain, LEVY, Christelle, MOURET-REYNIER, Marie-Ange, HARDY-BESSARD, Anne-Claire, LORTHOLARY, Alain, GRENIER, Julien, CHAKIBA, Camille, STEFANI, Laetitia, SOULIE, Patrick, JACQUIN, Jean-Philippe, PLAZA, Jérôme Edouard, CLATOT, Florian, TEIXEIRA, Luis, D'HONDT, Véronique, VEGAS, Hélène, DERBEL, Olfa, GARNIER TIXIDRE, Claire, DELBALDO, Catherine, MOREAU, Lionel, CHENEAU, Caroline, PAITEL, Jean-François, BERNARD-MARTY, Chantal, SPAETH, Dominique, GENET, Dominique, MOULLET, Isabelle, BONICHON-LAMICHHANE, Nathalie, DEIANA, Laura, GREILSAMER, Charlotte, VENAT-BOUVET, Laurence, DELECROIX, Valérie, MELIS, Adrien, ORFEUVRE, Hubert, NGUYEN, Suzanne, LEGOUFFE, Eric, ZANNETTI, Alain, LE SCODAN, Romuald, DOHOLLOU, Nadine, DALIVOUST, Philippe, ARSENE, Olivier, MARQUES, Nathalie, PETIT, Thierry, MOLLON, Delphine, DAUBA, Jérôme, BONNIN, Nathalie, MORVAN, François, GARDNER, Miriam, MARTI, Adina, LEVACHE, Charles-Briac, LACHAIER, Emma, ACHILLE, Mihaela, VALMAR, Christophe, BOUAITA, Ryan, MEDIONI, Jacques, FOA, Cyril, DEL PIANO, Francesco, GOZY, Michel, ESCANDE, Anne, LEDUC, Nicolas, LUCAS, Brigitte, MILLE, Dominique, AMMARGUELLAT, Hanifa, NAJEM, Abeer, TROUBOUL, Fanny, BARTHELEMY, Philippe, DESCLOS, Hervé, MAYEUR, Didier, LORCHEL, Fabrice, GUINET, François, LAURENTY, Anne-Pascale, BOUDRANT, Axelle, GISSEROT, Olivier, ALLEAUME, Corinne, DE GRAMONT, Aimery, Bidard, François-Clément, Hardy-Bessard, Anne-Claire, Dalenc, Florence, Bachelot, Thomas, Pierga, Jean-Yves, de la Motte Rouge, Thibault, Sabatier, Renaud, Dubot, Coraline, Frenel, Jean-Sébastien, Ferrero, Jean Marc, Ladoire, Sylvain, Levy, Christelle, Mouret-Reynier, Marie-Ange, Lortholary, Alain, Grenier, Julien, Chakiba, Camille, Stefani, Laetitia, Plaza, Jérôme Edouard, Clatot, Florian, Teixeira, Luis, D'Hondt, Véronique, Vegas, Hélène, Derbel, Olfa, Garnier-Tixidre, Claire, Canon, Jean-Luc, Pistilli, Barbara, André, Fabrice, Arnould, Laurent, Pradines, Anne, Bièche, Ivan, Callens, Céline, Lemonnier, Jérôme, Berger, Frédérique, and Delaloge, Suzette

Published
2022
Full Text
View/download PDF

21. Deformation under flow and morphological recovery of cancer cells.

Author

Gasser, Emile, Su, Emilie, Vaidηiulytė, Kotryna, Abbade, Nassiba, Cognart, Hamizah, Manneville, Jean-Baptiste, Viovy, Jean-Louis, Piel, Matthieu, Pierga, Jean-Yves, Terao, Kyohei, and Villard, Catherine

Subjects
MICROFLUIDIC devices, BLOOD circulation, SHEARING force, CELL membranes, CANCER cells
Abstract

The metastatic cascade includes a blood circulation step for cells detached from the primary tumor. This stage involves significant shear stress as well as large and fast deformation as the cells circulate through the microvasculature. These mechanical stimuli are well reproduced in microfluidic devices. However, the recovery dynamics after deformation is also pivotal to understand how a cell can pass through the multiple capillary constrictions encountered during a single hemodynamic cycle. The microfluidic system developed in this work allows single cell recovery to be studied under flow-free conditions following pressure-actuated cell deformation inside constricted microchannels. We used three breast cancer cell lines – namely MCF-7, SK-BR3 and MDA-MB231 – as cellular models representative of different cancer phenotypes. Changing the size of the constriction allows exploration of moderate to strong deformation regimes, the latter being associated with the formation of plasma membrane blebs. In the regime of moderate deformation, all cell types display a fast elastic recovery behavior followed by a slower viscoelastic regime, well described by a double exponential decay. Among the three cell types, cells of the mesenchymal phenotype, i.e. the MDA-MB231 cells, are softer and the most fluid-like, in agreement with previous studies. Our main finding here is that the fast elastic recovery regime revealed by our novel microfluidic system is under the control of cell contractility ensured by the integrity of the cell cortex. Our results suggest that the cell cortex plays a major role in the transit of circulating tumor cells by allowing their fast morphological recovery after deformation in blood capillaries. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic

Author

Bizot, Alexandra, Karimi, Maryam, Rassy, Elie, Heudel, Pierre Etienne, Levy, Christelle, Vanlemmens, Laurence, Uzan, Catherine, Deluche, Elise, Genet, Dominique, Saghatchian, Mahasti, Giacchetti, Sylvie, Grenier, Juline, Patsouris, Anne, Dieras, Véronique, Pierga, Jean-Yves, Petit, Thierry, Ladoire, Sylvain, Jacot, William, Benderra, Marc-Antoine, De Jesus, Anne, Delaloge, Suzette, Lambertini, Matteo, and Pistilli, Barbara

Published
2021
Full Text
View/download PDF

24. Non-invasive multi-cancer diagnosis using DNA hypomethylation of LINE-1 retrotransposons

Author

Michel, Marc, primary, Heidary, Maryam, additional, Mechri, Anissa, additional, Da Silva, Kevin, additional, Gorse, Marine, additional, von Grafenstein, Klaus, additional, Hego, Caroline, additional, Rampanou, Aurore, additional, Lamy, Constance, additional, Kamal, Maud, additional, Le Tourneau, Christophe, additional, Sene, Mathieu, additional, Bieche, Ivan, additional, Reyes, Cecile, additional, Gentien, David, additional, Stern, Marc-Henri, additional, Lantz, Olivier, additional, Cabel, Luc, additional, Pierga, Jean-Yves, additional, Bidard, Francois-Clement, additional, Azencott, Chloe-Agathe, additional, and Proudhon, Charlotte, additional

Published
2024
Full Text
View/download PDF

26. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis

Author

Hartkopf, Andreas D., Brucker, Sara Y., Taran, Florin-Andrei, Harbeck, Nadia, von Au, Alexandra, Naume, Bjørn, Pierga, Jean-Yves, Hoffmann, Oliver, Beckmann, Matthias W., Rydén, Lisa, Fehm, Tanja, Aft, Rebecca, Solà, Montserrat, Walter, Vincent, Rack, Brigitte, Schuetz, Florian, Borgen, Elin, Ta, Minh-Hanh, Bittner, Ann-Kathrin, Fasching, Peter A., Fernö, Mårten, Krawczyk, Natalia, Weilbaecher, Katherine, Margelí, Mireia, Hahn, Markus, Jueckstock, Julia, Domschke, Christoph, Bidard, Francois-Clement, Kasimir-Bauer, Sabine, Schoenfisch, Birgitt, Kurt, Ayse G., Wallwiener, Markus, Gebauer, Gerhard, Klein, Christoph A., Wallwiener, Diethelm, Janni, Wolfgang, and Pantel, Klaus

Published
2021
Full Text
View/download PDF

27. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy

Author

Rodrigues-Ferreira, Sylvie, Nehlig, Anne, Moindjie, Hadia, Monchecourt, Clarisse, Seiler, Cynthia, Marangoni, Elisabetta, Chateau-Joubert, Sophie, Dujaric, Marie-Eglantine, Servant, Nicolas, Asselain, Bernard, deCremoux, Patricia, Lacroix-Triki, Magali, Arnedos, Monica, Pierga, Jean-Yves, André, Fabrice, and Nahmias, Clara

Published
2019

29. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Author

Piccart, Martine, van 't Veer, Laura J, Poncet, Coralie, Lopes Cardozo, Josephine M N, Delaloge, Suzette, Pierga, Jean-Yves, Vuylsteke, Peter, Brain, Etienne, Vrijaldenhoven, Suzan, Neijenhuis, Peter A, Causeret, Sylvian, Smilde, Tineke J, Viale, Giuseppe, Glas, Annuska M, Delorenzi, Mauro, Sotiriou, Christos, Rubio, Isabel T, Kümmel, Sherko, Zoppoli, Gabriele, Thompson, Alastair M, Matos, Erika, Zaman, Khalil, Hilbers, Florentine, Fumagalli, Debora, Ravdin, Peter, Knox, Susan, Tryfonidis, Konstantinos, Peric, Aleksandra, Meulemans, Bart, Bogaerts, Jan, Cardoso, Fatima, and Rutgers, Emiel J T

Published
2021
Full Text
View/download PDF

30. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023

Author

Aapro, Matti, Al-Ghazali, Hesham, Bachelot, Thomas, Barranger, Emmanuel, Berrada, Narjiss, Bidard, François-Clément, Bounedjar, Adda, Boussen, Hamouda, Campone, Mario, Cardoso, Fatima, Ceugnart, Luc, Classe, Jean-Marc, Cohen, Monique, Coutant, Charles, Cutuli, Bruno, Dalenc, Florence, Dieras, Véronique, Dohollou, Nadine, Giacchetti, Sylvie, Goncalves, Anthony, Freyer, Gilles, Hannoun-Levi, Jean-Michel, Hardy-Bessard, Anne-Claire, Jacquin, Jean-Philippe, Jacot, William, Kerrou, Khaldoun, Ladoire, Sylvain, Lerebours, Florence, Levy, Christelle, Llombart-Cussac, Antonio, Loirat, Delphine, Thomassin, Isabelle, Piccart, Martine, Petit, Thierry, Radosevic-Robin, Nina, Rotenberg, Luc, Rouzier, Roman, Salmon, Rémy, Vincent-Salomon, Anne, Spano, Jean-Philippe, Tallet, Agnès, Teixera, Luis, Tredan, Olivier, Verret, Benjamin, Zarca, Daniel, Zelek, Laurent, Zerbib, Eric, Gligorov, Joseph, Benderra, Marc-Antoine, Barthere, Xavier, de Forceville, Louise, Antoine, Eric Charles, Cottu, Paul Henri, Delaloge, Suzette, Pierga, Jean-Yves, Belkacemi, Yazid, Houvenaegel, Gilles, Pujol, Pascal, Rivera, Sofia, Spielmann, Marc, Penault-Llorca, Frédérique, and Namer, Moise

Published
2023
Full Text
View/download PDF

33. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

Author

Coudert, Bruno, Pierga, Jean-Yves, Mouret-Reynier, Marie-Ange, Kerrou, Kaldoun, Ferrero, Jean-Marc, Petit, Thierry, Du, Fanny Le, Dupré, Pierre-François, Bachelot, Thomas, Gabelle, Philippe, Chauvet, Marie-Pierre, Coeffic, David, Barbe, Catherine, Prevost, Jean-Briac, Paintaud, Gilles, Thibault, Gilles, Ferhat, Abdennour, Dupin, Julien, Berriolo-Riedinger, Alina, and Arnould, Laurent

Published
2020
Full Text
View/download PDF

35. COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)

Author

Gligorov, Joseph, Bachelot, Thomas, Pierga, Jean-Yves, Antoine, Eric-Charles, Balleyguier, Corinne, Barranger, Emmanuel, Belkacemi, Yazid, Bonnefoi, Hervé, Bidard, François-Clément, Ceugnart, Luc, Classe, Jean-Marc, Cottu, Paul, Coutant, Charles, Cutuli, Bruno, Dalenc, Florence, Darai, Emile, Dieras, Veronique, Dohollou, Nadine, Giacchetti, Sylvie, Goncalves, Anthony, Hardy-Bessard, Anne-Claire, Houvenaeghel, Gilles, Jacquin, Jean-Philippe, Jacot, William, Levy, Christelle, Mathelin, Carole, Nisand, Israel, Petit, Thierry, Poncelet, Edouard, Rivera, Sofia, Rouzier, Roman, Salmon, Rémy, Scotté, Florian, Spano, Jean-Philippe, Uzan, Catherine, Zelek, Laurent, Spielmann, Marc, Penault-Llorca, Frédérique, Namer, Moise, and Delaloge, Suzette

Published
2020
Full Text
View/download PDF

36. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023

Author

Gligorov, Joseph, primary, Benderra, Marc-Antoine, additional, Barthere, Xavier, additional, de Forceville, Louise, additional, Antoine, Eric Charles, additional, Cottu, Paul Henri, additional, Delaloge, Suzette, additional, Pierga, Jean-Yves, additional, Belkacemi, Yazid, additional, Houvenaegel, Gilles, additional, Pujol, Pascal, additional, Rivera, Sofia, additional, Spielmann, Marc, additional, Penault-Llorca, Frédérique, additional, Namer, Moise, additional, Aapro, Matti, additional, Al-Ghazali, Hesham, additional, Bachelot, Thomas, additional, Barranger, Emmanuel, additional, Berrada, Narjiss, additional, Bidard, François-Clément, additional, Bounedjar, Adda, additional, Boussen, Hamouda, additional, Campone, Mario, additional, Cardoso, Fatima, additional, Ceugnart, Luc, additional, Classe, Jean-Marc, additional, Cohen, Monique, additional, Coutant, Charles, additional, Cutuli, Bruno, additional, Dalenc, Florence, additional, Dieras, Véronique, additional, Dohollou, Nadine, additional, Giacchetti, Sylvie, additional, Goncalves, Anthony, additional, Freyer, Gilles, additional, Hannoun-Levi, Jean-Michel, additional, Hardy-Bessard, Anne-Claire, additional, Jacquin, Jean-Philippe, additional, Jacot, William, additional, Kerrou, Khaldoun, additional, Ladoire, Sylvain, additional, Lerebours, Florence, additional, Levy, Christelle, additional, Llombart-Cussac, Antonio, additional, Loirat, Delphine, additional, Thomassin, Isabelle, additional, Piccart, Martine, additional, Petit, Thierry, additional, Radosevic-Robin, Nina, additional, Rotenberg, Luc, additional, Rouzier, Roman, additional, Salmon, Rémy, additional, Vincent-Salomon, Anne, additional, Spano, Jean-Philippe, additional, Tallet, Agnès, additional, Teixera, Luis, additional, Tredan, Olivier, additional, Verret, Benjamin, additional, Zarca, Daniel, additional, Zelek, Laurent, additional, and Zerbib, Eric, additional

Published
2023
Full Text
View/download PDF

37. Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns

Author

Gougis, Paul, primary, Grandal, Beatriz, additional, Jochum, Floriane, additional, Bihan, Kevin, additional, Coussy, Florence, additional, Barraud, Solenn, additional, Asselain, Bernard, additional, Dumas, Elise, additional, Sebbag, Clara, additional, Hotton, Judicael, additional, Spaggiari, Emmanuel, additional, Pierga, Jean-Yves, additional, Savarino, Raphaëlle, additional, Laas, Enora, additional, Spano, Jean-Philippe, additional, Reyal, Fabien, additional, and Hamy, Anne-Sophie, additional

Published
2023
Full Text
View/download PDF

39. Tolerance of concurrent adjuvant radiotherapy and pembrolizumab for triple negative breast cancer: real life experience

Author

Tison, Thais, primary, Loap, Pierre, additional, Arnaud, Emilie, additional, Cao, Kim, additional, Bringer, Solene, additional, Kissel, Manon, additional, Maaradji, Safia, additional, Mainguene, Juliette, additional, Pierga, Jean-Yves, additional, Lerebours, Florence, additional, Vincent-Salomon, Anne, additional, Mirabelle, Mariana, additional, Bidard, Francois-Clement, additional, Loirat, Delphine, additional, and Kirova, Youlia M., additional

Published
2023
Full Text
View/download PDF

40. Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer

Author

Bortolini Silveira, Amanda, Bidard, François-Clément, Tanguy, Marie-Laure, Girard, Elodie, Trédan, Olivier, Dubot, Coraline, Jacot, William, Goncalves, Anthony, Debled, Marc, Levy, Christelle, Ferrero, Jean-Marc, Jouannaud, Christelle, Rios, Maria, Mouret-Reynier, Marie-Ange, Dalenc, Florence, Hego, Caroline, Rampanou, Aurore, Albaud, Benoit, Baulande, Sylvain, Berger, Frédérique, Lemonnier, Jérôme, Renault, Shufang, Desmoulins, Isabelle, Proudhon, Charlotte, and Pierga, Jean-Yves

Published
2021
Full Text
View/download PDF

43. Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study

Author

Alhenc-Gelas, Marion, Cabel, Luc, Berger, Frederique, Delaloge, Suzette, Frenel, Jean-Sebastien, Levy, Christelle, Firmin, Nelly, Ladoire, Sylvain, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Dalenc, Florence, Loirat, Delphine, Dubot, Coraline, Vuagnat, Perrine, Deluche, Elise, Mokdad-Adi, Meriem, Patsouris, Anne, Annic, Josselin, Djerroudi, Lounes, Lavigne, Marion, Pierga, Jean-Yves, Coppo, Paul, and Bidard, Francois-Clement

Published
2021
Full Text
View/download PDF

45. Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

Author

Vasseur, Antoine, Cabel, Luc, Tredan, Olivier, Chevrier, Marion, Dubot, Coraline, Lorgis, Véronique, Jacot, William, Goncalves, Anthony, Debled, Marc, Levy, Christelle, Ferrero, Jean-Marc, Jouannaud, Christelle, Luporsi, Elisabeth, Mouret-Reynier, Marie-Ange, Dalenc, Florence, Lemonnier, Jerome, Savignoni, Alexia, Tanguy, Marie-Laure, Bidard, Francois-Clement, and Pierga, Jean-Yves

Published
2020
Full Text
View/download PDF

47. Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

Author

Lerebours, Florence, Pulido, Marina, Fourme, Emmanuelle, Debled, Marc, Becette, Véronique, Bonnefoi, Hervé, Rivera, Sofia, MacGrogan, Gaetan, Mouret-Reynier, Marie-Ange, de Lara, Christine Tunon, Pierga, Jean-Yves, Breton-Callu, Christel, Venat-Bouvet, Laurence, Mathoulin-Pélissier, Simone, de la Motte rouge, Thibault, Dalenc, Florence, Sigal, Brigitte, Bachelot, Thomas, Lemonnier, Jérôme, and Quenel-Tueux, Nathalie

Published
2020
Full Text
View/download PDF

50. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Author

Bossuyt, V, Provenzano, E, Symmans, WF, Boughey, JC, Coles, C, Curigliano, G, Dixon, JM, Esserman, LJ, Fastner, G, Kuehn, T, Peintinger, F, von Minckwitz, G, White, J, Yang, W, Badve, S, Denkert, C, MacGrogan, G, Penault-Llorca, F, Viale, G, Cameron, D, collaboration, Breast International Group-North American Breast Cancer Group, Earl, Helena, Alba, Emilio, Lluch, Ana, Albanell, Joan, Amos, Keith, Biernat, Wojciech, Bonnefoi, Hervé, Buzdar, Aman, Cane, Paul, Pinder, Sarah, Carson, Lesley, Dickson-Witmer, Diana, Gong, Gyungyub, Green, Jimmy, Hsu, Chih-Yi, Tseng, Ling-Ming, Kroep, Judith, Leitch, A Marilyn, Sarode, Venetia, Mamounas, Eleftherios, Marcom, Paul Kelly, Nuciforo, Paolo, Paik, Soonmyung, Peg, Vicente, Peston, David, Pierga, Jean-Yves, Quintela-Fandino, Miguel, Salgado, Roberto, Sikov, William, Thomas, Jeremy, Unzeitig, Gary, and Wesseling, Jelle

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Breast Cancer, Cancer, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Clinical Trials as Topic, Female, Humans, Neoadjuvant Therapy, Neoplasm Staging, Neoplasm, Residual, Practice Guidelines as Topic, Prognosis, breast cancer, neoadjuvant systemic therapy, residual disease, pathologic complete response, pathologic assessment, response evaluation, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post-NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response (pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site (clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR (ypT0/is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results